Please login to the form below

Not currently logged in
Email:
Password:

GlycoVaxyn appoints Gerd Zettlmeissl as chairman

He will join the Swiss vaccines company in June

Swiss vaccines company GlycoVaxyn has appointed Gerd Zettlmeissl as chairman of the board of directors with effect from June, when he will take over from Michel Greco.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company," Greco said.

"Having chaired the board for more than seven years, I will work very closely with Gerd to ensure a smooth transition," he added.

Zettlmeissl has more than 20 years of experience in developing and commercialising vaccines and spent almost 10 years in executive positions at Intercell.

He served first as its chief operating officer from 2001 to 2005 and then as CEO from 2005 until May  2011.

Prior to joining Intercell, Zettlmeissl served as international head of industrial and quality operations at Chiron Vaccines, and managing director of Chiron Behring GmbH & Co.

He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.

6th March 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....